Efficacy and safety of outpatient treatment based on the hestia clinical decision rule with or without N-terminal pro-brain natriuretic peptide testing in patients with acute pulmonary embolism: A randomized clinical trial

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 8, 2016, Pages 998-1006

  Den Exter, Paul L ^a   Zondag, Wendy ^a   Klok, Frederikus A ^a   Brouwer, Rolf E ^b   Dolsma, Janneke ^c   Eijsvoge, Michiel ^d   Faber, Laura M ^e   Van Gerwen, Marijke ^f   Grootenboers, Marco J ^g   Heller Baan, Roxane ^h   Hovens, Marcel M ⁱ   Jonkers, Gé J P M ^j   Van Kralingen, Klaas W ^k   Melissant, Christian F ^l   Peltenburg, Henny ^m   Post, Judith P ⁿ   Van De Ree, Marcel A ^o   Vlasveld, L Th ^p   De Vreede, Mariëlle J ^p   Huisman, Menno V ^a   Blox, W J B ^g   Langeveld, T J C ^p   Van Rossum, A P ^p   Cornage E ^o   Koster, T ^m   Besemer, F ^m   Eshuis, M ^m   Mairuhu, A T ^q   Heller, R ^h   Huisman, M V ^a   Cobbaert, C M ^a   Ramai, S R S ^a   Heringhaus, C ^a   Mos, I C M ^p   Hiddinga, B ^d   Ootjers, C ^j   De Groot, K D ^j   Kaasjager, H A H ⁱ   Hazelaar, G ⁱ   Onstein, C ^l   Kramer, M H H ⁿ   Hofstee, H M A ⁿ   Serne, E ⁿ   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b REINIER DE GRAAF HOSPITAL   (Netherlands)

^c Diaconessenhuis ^*  (Netherlands)

^d MEDISCH SPECTRUM TWENTE   (Netherlands)

^e RED CROSS HOSPITAL   (Netherlands)

^f HAGA HOSPITAL   (Netherlands)

^g AMPHIA HOSPITAL   (Netherlands)

^h IKAZIA HOSPITAL   (Netherlands)

ⁱ RIJNSTATE HOSPITAL   (Netherlands)

^j RIJNLAND HOSPITAL   (Netherlands)

^k Bethesda Hospital   (Netherlands)

^l Department of Orthopaedic Surgery   (Netherlands)

^m GROENE HART HOSPITAL   (Netherlands)

ⁿ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^o DEPARTMENT OF SURGERY   (Netherlands)

^p MEDICAL CENTER HAAGLANDEN   (Netherlands)

^q HAGA Medical Centre   (Netherlands)

more..

Author keywords

Outpatient Treatment; Pulmonary embolism; Risk stratification

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMOPERICARDIUM; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SAINT MARTIN (DUTCH); VENOUS THROMBOEMBOLISM; BLOOD; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DECISION SUPPORT SYSTEM; DIAGNOSTIC IMAGING; INTENSIVE CARE UNIT; MORTALITY; PULMONARY EMBOLISM; RESUSCITATION; STATISTICS AND NUMERICAL DATA;

CARDIOPULMONARY RESUSCITATION; COMPUTED TOMOGRAPHY ANGIOGRAPHY; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PATIENT DISCHARGE; PEPTIDE FRAGMENTS; PULMONARY EMBOLISM;

EID: 84992365670     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201512-2494OC     Document Type: Article

References (27)

1. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-699.
2. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH; Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-687.
3. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. A comparison of low-molecularweight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681.
4. Zondag W, Kooiman J, Klok FA, Dekkers OM, Huisman MV. Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J 2013;42:134-144.
5. Agterof MJ, Schutgens RE, Snijder RJ, Epping G, Peltenburg HG, Posthuma EF, Hardeman JA, van der Griend R, Koster T, Prins MH, et al. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. J Thromb Haemost 2010;8: 1235-1241.
6. Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, Renaud B, Verhamme P, Stone RA, Legall C, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011;378:41-48.
7. Erkens PM, Gandara E, Wells P, Shen AY, Bose G, Le Gal G, Rodger M, Prins MH, Carrier M. Safety of outpatient treatment in acute pulmonary embolism. J Thromb Haemost 2010;8:2412-2417.
8. Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost 2000;83:209-211.
9. Wells PS, Anderson DR, Rodger MA, Forgie MA, Florack P, Touchie D, Morrow B, Gray L, O'Rourke K, Wells G, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005;165:733-738.
10. Zondag W, Mos IC, Creemers-Schild D, Hoogerbrugge AD, Dekkers OM, Dolsma J, Eijsvogel M, Faber LM, Hofstee HM, Hovens MM, et al.; Hestia Study Investigators. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011;9:1500-1507.
11. Aujesky D, Smith KJ, Cornuz J, Roberts MS. Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. Chest 2005;128:1601-1610.
12. Konstantinides S, Goldhaber SZ. Pulmonary embolism: risk assessment and management. Eur Heart J 2012;33:3014-3022.
13. Becattini C, Casazza F, Forgione C, Porro F, Fadin BM, Stucchi A, Lignani A, Conte L, Imperadore F, Bongarzoni A, et al. Acute pulmonary embolism: external validation of an integrated risk stratification model. Chest 2013;144:1539-1545.
14. Jiménez D, Aujesky D, Moores L, Gómez V, Martí D, Briongos S, Monreal M, Barrios V, Konstantinides S, Yusen RD. Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. Thorax 2011;66: 75-81.
15. den Exter PL, Zondag W, Klok FA, Brouwer R, Dolsma J, Eijsvogel M, Faber LM, Grootenboers MJ, Herller R, Hovens MM, et al. Efficacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without NT-proBNP testing in patients with acute pulmonary embolism: a randomized trial [abstract]. J Thromb Haemost 2015;13:193.
16. Kucher N, Printzen G, Doernhoefer T, Windecker S, Meier B, Hess OM. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003;107: 1576-1578.
17. Kara K, Lehmann N, Neumann T, Kälsch H, Möhlenkamp S, Dykun I, Broecker-Preuss M, Pundt N, Moebus S, Jöckel KH, et al. NTproBNP is superior to BNP for predicting first cardiovascular events in the general population: the Heinz Nixdorf Recall Study. Int J Cardiol 2015;183:155-161.
18. Taylor CJ, Roalfe AK, Iles R, Hobbs FD. The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis. BMJ Open 2014;4:e004675.
19. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141:e419S-e494S.
20. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3: 692-694.
21. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A,Cornuz J, Roy PM, Fine MJ. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005;172:1041-1046.
22. Jiménez D, Aujesky D, Moores L, Gómez V, Lobo JL, Uresandi F, Otero R, Monreal M, Muriel A, Yusen RD; RIETE Investigators. Simplification of the Pulmonary Embolism Severity Index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010;170:1383-1389.
23. Vuilleumier N, Le Gal G, Verschuren F, Perrier A, Bounameaux H, Turck N, Sanchez JC, Mensi N, Perneger T, Hochstrasser D, et al. Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. J Thromb Haemost 2009;7:391-398.
24. Lankeit M, Jiménez D, Kostrubiec M, Dellas C, Kuhnert K, Hasenfuß G, Pruszczyk P, Konstantinides S. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014;43:1669-1677.
25. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008;178:425-430.
26. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, et al.; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;35:3033-3069, 3069a-3069k.
27. Beam DM, Kahler ZP, Kline JA. Immediate discharge and home treatment with rivaroxaban of low-risk venous thromboembolism diagnosed in two U.S. emergency departments: a one-year preplanned analysis. Acad Emerg Med 2015;22:788-795.